“By leveraging the latest advances in our ADAPT tissue technology to create a three-dimensional, single-piece moulded valve which securely attaches to a stent with minimal sutures, we anticipate a substantial reduction in the cost of manufacturing a TAVR device.”
“We believe that the combination of our clinically-superior ADAPT treated tissue, three-leaflet, single-piece valve design and patented hydro-packaging, has the potential to deliver the most unique, high-quality and cost-effective TAVR product on the market.” (my bold)
great news....ADAPT continues to provide AHZ with an ongoing product platform that will result in a distinct competitive advantage for many many years to come...imo, comparisons with CSL and COH are not pipe dreams so long as we can keep predators at bay in the future...
...once again hats off to Prof Neethling, his fantastic team of brilliant minds and for WP et al in their focused efforts to rapidly commercialise this technology
Ann: Admedus update on TAVR project, page-17
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.65 |
Change
-0.060(0.38%) |
Mkt cap ! $300.8M | |||
| Open | High | Low | Value | Volume |
| $15.72 | $15.85 | $15.51 | $1.660M | 117.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 312 | $15.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.65 | 626 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |